Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

・The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r pediatric B-cell ALL and r/r DLBCL
・Novartis is the only company with an approved CAR-T cell therapy for pediatric r/r B-cell ALL and the first to receive approval in two distinct indications, both in the EU and the US
・Novartis continues its strategy to expand manufacturing facilities with agreements with external collaborators, such as CELLforCURE in France



Leave a comment

Your email address will not be published.